We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Amid an ongoing dispute with the National Institutes of Health (NIH) over who exactly invented the mRNA sequence of Moderna’s COVID-19 vaccine, the company is hitting the pause button on pursuing a patent for the sequence. Read More
The European Medicines Agency’s (EMA) human medicines committee endorsed granting 13 marketing authorizations for drugs during its monthly meeting, held Dec. 13 to 16. Read More
Regeneron and AstraZeneca both say their therapeutic antibody cocktails remain active against Omicron, but questions remain in light of a Chinese study concluding that the variant escapes 85 percent of tested antibodies. Read More
In what could turn out to be a fatal blow for the nearly $2 trillion Build Back Better spending package that included drug pricing reform provisions, Sen. Joe Manchin (D-W.Va.) said Sunday that he definitely will not vote for the landmark legislation. Read More
The FDA has called out Endo International, maker of Vasostrict, saying the agency plans to ask the Federal Trade Commission (FTC) to investigate Endo for “anticompetitive business practices” after the company pressed FDA to block generics of its best-selling drug. Read More
In another huge blow to Biogen’s controversial Alzheimer’s blockbuster, the European Medicines Agency (EMA) has declined to approve Aduhelm (aducanumab), saying the data don’t support a strong clinical benefit and studies did not show that the medicine was sufficiently safe. Read More